Market revenue in 2023 | USD 3,467.6 million |
Market revenue in 2030 | USD 9,814.9 million |
Growth rate | 16% (CAGR from 2023 to 2030) |
Largest segment | Tavr (transcatheter aortic valve replacement) |
Fastest growing segment | LAAC (Left Atrial Appendage Closure) |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | SAVR (Surgical Aortic Valve Replacement), TAVR (Transcatheter Aortic Valve Replacement), Mitral Repair (Annuloplasty), LAAC (Left Atrial Appendage Closure) |
Key market players worldwide | Boston Scientific Corp, Medtronic PLC, Edwards Lifesciences Corp, Abbott Laboratories, St. Jude Medical, LivaNova PLC, Stryker Corp, Lepu Medical, Biomerics, CardioKinetix |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to structural heart devices market will help companies and investors design strategic landscapes.
Tavr (transcatheter aortic valve replacement) was the largest segment with a revenue share of 54.31% in 2023. Horizon Databook has segmented the Europe structural heart devices market based on savr (surgical aortic valve replacement), tavr (transcatheter aortic valve replacement), mitral repair (annuloplasty), laac (left atrial appendage closure) covering the revenue growth of each sub-segment from 2018 to 2030.
The Europe structural heart devices market is experiencing a dynamic evolution, driven by a combination of factors such as the increasing incidence of Structural Heart Diseases (SHD), technological advancements in medical devices, and the robust healthcare infrastructure across the continent.
A study published in the European Heart Journal in 2018 highlighted that around 180,000 patients in the European Union and Northern America could be potential candidates for Transcatheter Aortic Valve Implantation (TAVI) annually. This number is projected to rise to 270,000 if the indications for TAVI are expanded to include low-risk patients.
This growing demand for structural heart devices is fueled by the need for more advanced treatment options, such as the development of innovative heart valves and annuloplasty rings, opening up new avenues for market expansion.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe structural heart devices market , including forecasts for subscribers. This continent databook contains high-level insights into Europe structural heart devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account